Print

Cardionovum® Poised for Rapid Commercialization of Its Drug-Coated Balloons (DCB) and Drug-Eluting Stents (DES) in 57 Countries Outside of U.S.  
10/9/2012 9:36:15 AM

BONN, Germany--(BUSINESS WIRE)--Cardionovum GmbH announced today that it has established its distribution network in 57 countries since the beginning of 2012.

The Company is commercializing its CE-marked Paclitaxel-coated drug-coated balloon (DCB) for (1) coronary (PRIMUS®) and (2) peripheral (LEGFLOW®) applications since March 2012. Additionally, Cardionovum expects to launch before year-end a next-generation Sirolimus-eluting coronary stent system—PROLIMUS® Biograde, whose design combines proven pro-healing features to promote early re-endothelialization.

//-->